|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD
913.72 Million
|
|
CAGR (2025-2030)
|
6.46%
|
|
Fastest Growing Segment
|
Genomics
|
|
Largest Market
|
West India
|
|
Market Size (2030)
|
USD 1,341.94 Million
|
Market Overview
India Life Science Tools Market was
valued at USD 913.72 Million in 2024 and is expected to reach USD 1,341.94 Million
by 2030 with a CAGR of 6.46% during the forecast period.
The India Life Science
Tools Market is experiencing rapid growth, driven by the expansion of the
biopharmaceutical and biotechnology sectors, increasing investments in research
and development (R&D), and the rising adoption of genomics, proteomics, and
molecular diagnostics. The presence of a strong pharmaceutical base in
Maharashtra and Gujarat, coupled with biotech hubs in Bengaluru and Hyderabad,
has positioned India as a key market for life science tools.
Government
initiatives such as the Genome India Project, Production Linked Incentive (PLI)
scheme, and funding from ICMR and DBT are accelerating advancements in
genomics, precision medicine, and drug discovery, further boosting demand for
high-end analytical instruments and reagents. Additionally, the increasing
burden of chronic diseases like cancer and diabetes is driving demand for
molecular diagnostics, gene sequencing, and cell biology tools.
However, the market faces challenges
such as high costs of advanced technologies, limited skilled workforce, and
dependency on imported equipment, which increases operational expenses for
research institutions and pharmaceutical firms. While government incentives
encourage domestic manufacturing, India still lags in developing high-end
genomic and proteomic analysis tools, making affordability a key concern.
Infrastructure gaps in tier-2 and tier-3 cities also restrict market
penetration, limiting accessibility to cutting-edge life science research.
Despite these challenges, the entry of global players, increased foreign
investments, and a growing focus on personalized medicine are expected to drive
sustained growth in the Indian life science tools market in the coming years.
Key Market Drivers
Expansion
of Biotechnology Sector
India's biotechnology sector has witnessed remarkable
expansion over the past decade, emerging as a pivotal driver of economic growth
and innovation. In 2014, the industry's valuation stood at approximately $10
billion; by 2024, it had surged to over $130 billion, with projections aiming
for $300 billion by 2030.
This exponential growth is underpinned by a robust
startup ecosystem, significant government initiatives, and a burgeoning
bioeconomy. The startup landscape has been particularly dynamic. From a
modest count of around 300 biotech startups in 2012, the number escalated to
over 9,000 by 2024. These startups span diverse domains, including
health-tech, diagnostics, agriculture, and bioinformatics, contributing to over
800 innovative products and attracting $600 million in follow-on funding. This
surge not only fosters innovation but also positions India as a global hub for
biotechnology solutions.
Government support has been instrumental in this
trajectory. The flagship Startup India program, launched in 2016, has
recognized over 157,000 startups across sectors as of December 2024,
streamlining compliance and offering tax benefits to nurture entrepreneurial
ventures. Specific to biotechnology, the Biotechnology Industry Research
Assistance Council (BIRAC) has played a pivotal role since its inception in
2012, fostering innovation and facilitating the transition of research from
laboratories to market-ready applications. This concerted effort has
cultivated a conducive environment for biotech enterprises to thrive. The
bioeconomy, encompassing all economic activity derived from biotechnological
research and innovation, has expanded from $10 billion in 2014 to over $130
billion in 2024.
This growth is driven by increasing demand for
biopharmaceuticals, vaccines, and sustainable agricultural solutions. Notably,
India accounts for 60% of global vaccine production and houses the
second-largest number of USFDA-approved manufacturing plants outside the United
States, underscoring its critical role in global healthcare.
Growing
Demand for Precision Medicine & Diagnostics
The rising demand for precision medicine and diagnostics is transforming India’s healthcare landscape, driven by advancements in genomics, molecular biology, and AI. The genetic testing market, valued at USD 69.24 million in 2024, is expanding beyond metro cities due to increased awareness, wider physician adoption, and declining costs. Technologies like next-generation sequencing (NGS) have improved affordability, with tests such as BRCA1/2 and NIPT becoming 30–40% cheaper.
AI adoption among clinicians has surged to 41% in 2025, significantly enhancing diagnostic accuracy and speed. Advanced tools like liquid biopsies, gene profiling, and proteomics are enabling real-time disease monitoring, particularly for cancer, cardiovascular conditions, and diabetes.
Pharmacogenomics is also gaining traction, supporting personalized treatments based on genetic variations, while initiatives like the Genome India Project and PRIP funding are accelerating research and accessibility. Overall, the convergence of genomics, AI, and policy support is driving a shift toward personalized healthcare and strengthening India’s position in precision medicine.
Download Free Sample Report
Key Market Challenges
High
Cost of Advanced Technologies
One of the biggest challenges in the
Indian life science tools market is the high cost of advanced technologies,
which limits accessibility and adoption, especially among smaller research
institutions, diagnostic labs, and pharmaceutical startups. Many cutting-edge
tools used in genomics, proteomics, and cell biology, such as next-generation
sequencing (NGS), mass spectrometry, and high-throughput screening systems,
require significant capital investment. These technologies often involve not
just the upfront cost of acquisition, but also substantial expenses related to
maintenance, consumables, and skilled personnel training, making them
financially burdensome for many players in the market.
India’s dependency on imported equipment
further escalates costs. A majority of high-end life science tools are sourced
from international manufacturers, leading to increased expenses due to import
duties, currency fluctuations, and logistical costs. Unlike developed
countries, where governments and private sector investments significantly
subsidize R&D, many Indian research institutions operate on constrained
budgets, limiting their ability to invest in advanced analytical instruments.
This creates a gap in technological accessibility between elite research
centers in metro cities and smaller institutions in tier-2 and tier-3 cities,
slowing down overall innovation and scientific progress.
Moreover, while government initiatives
such as the Atmanirbhar Bharat (Self-Reliant India) initiative aim to promote
local manufacturing of high-tech scientific instruments, the domestic
production of life science tools is still in its nascent stage. India’s biotech
and pharmaceutical sectors rely heavily on imported components and reagents,
further increasing operational costs. Limited availability of affordable,
high-precision domestic alternatives mean researchers and companies often have
to compromise on the quality or scale of their studies due to budgetary
constraints.
Key Market Trends
Growing
Biopharmaceutical Industry
The rapid expansion of India’s
biopharmaceutical industry is emerging as a major trend shaping the life
science tools market. With increasing demand for biosimilars, vaccines,
monoclonal antibodies, and gene therapies, the biopharma sector is driving significant
investment in advanced research tools, analytical technologies, and
high-throughput screening systems. The shift from traditional small-molecule
drugs to biologics has necessitated the adoption of sophisticated life science
instruments for protein analysis, cell culture, and bioprocessing, fueling
market growth.
One of the major factors contributing to
this trend is the rising global demand for cost-effective biologics and
biosimilars, where India has positioned itself as a key player. Indian
pharmaceutical companies are leveraging their expertise in generic drug
manufacturing to enter the biosimilar market, leading to increased investments
in R&D, regulatory compliance, and advanced analytical tools. With a strong
presence of contract development and manufacturing organizations (CDMOs), the
country is becoming a hub for outsourced biopharmaceutical research and
production, further amplifying the need for cutting-edge life science tools.
The rising adoption of personalized
medicine and the growing emphasis on cell and gene therapies are expanding the
need for high-end analytical techniques such as mass spectrometry, flow
cytometry, and chromatography. Companies are increasingly focusing on process
optimization and automation to improve the efficiency and scalability of
biopharmaceutical production, leading to higher adoption of single-use
bioprocessing systems, biosensors, and AI-driven quality control mechanisms.
Segmental Insights
Product
Insights
Based on Product, Next-Generation
Sequencing (NGS) have emerged as the dominating segment in the India Life
Science Tools Market in 2024, driven by its expanding applications in
genomic research, precision medicine, cancer diagnostics, and infectious
disease detection. The increasing adoption of whole-genome sequencing,
transcriptomics, and epigenetics studies has fueled the demand for NGS
technology in clinical diagnostics, drug development, and personalized
healthcare.
The Genome India Project, aimed at
sequencing the diverse genetic makeup of the Indian population, has
significantly boosted the use of NGS tools. Additionally, the growing
prevalence of genetic disorders, rare diseases, and cancer, along with the
decreasing cost of sequencing, has accelerated market penetration. The use of
NGS in non-invasive prenatal testing (NIPT), pharmacogenomics, and microbiome
research has further strengthened its position as the leading product category.
End
Use Insights
Based on End Use, Pharmaceutical &
Biotechnology Companies have emerged as the dominating segment in the India
Life Science Tools Market in 2024. The growing investment in R&D, clinical trials,
and precision medicine has fueled the demand for advanced analytical
instruments, genomic sequencing tools, and bioprocessing technologies within
this sector.
India’s strong position as a global pharmaceutical
manufacturing hub, particularly in biosimilars, vaccines, and monoclonal
antibodies, has led to increased adoption of next-generation sequencing (NGS),
mass spectrometry, flow cytometry, and chromatography systems. The rise of
contract development and manufacturing organizations (CDMOs), catering to
global biotech and pharma firms, has further strengthened the demand for life
science tools.
Government support through initiatives like the
Production-Linked Incentive (PLI) scheme and the National Biopharma Mission has
encouraged pharmaceutical and biotech firms to invest in cutting-edge research
infrastructure. With increasing focus on personalized medicine, regenerative
therapies, and AI-driven drug discovery, pharmaceutical and biotechnology
companies remain the leading end-user segment, driving growth in India's life
science tools market.
Download Free Sample Report
Regional Insights
Based on Region, West India have emerged
as the dominating region in the India Life Science Tools Market in 2024. It is
driven by its strong presence of pharmaceutical and biotechnology hubs, leading
research institutions, and a well-established healthcare ecosystem. States like
Maharashtra and Gujarat have played a crucial role in propelling the market
forward due to their concentration of pharma manufacturing, contract research
organizations (CROs), and life science startups.
Maharashtra, particularly Mumbai and
Pune, houses major pharmaceutical giants, research institutes, and biotech
parks. It is a key center for clinical research, drug discovery, and genomics
applications, boosting the demand for life science tools such as NGS, PCR, mass
spectrometry, and chromatography systems. The presence of top academic and
research institutions such as the National Institute for Research in
Reproductive Health (NIRRH) and the Indian Institute of Science Education and
Research (IISER) further supports market growth.
Recent Development
- In January 2026, Metropolis Healthcare launched its Centre of Genomics in India and deployed Illumina’s NovaSeq X Series for research purposes as part of the centre’s technology upgrade. The company said this high-throughput sequencing platform could generate more than 20,000 whole genomes annually and would improve throughput, accuracy, and scale for clinically actionable genomics, making it one of the clearest recent examples of advanced life science tool adoption in India.
- In September 2025, Uncoded by Premas Life Sciences launched a new R&D facility in New Delhi to strengthen India’s multi-omics capabilities and develop cost-effective, locally manufactured biotech tools. According to the report, the facility was equipped for assay development, molecular design, validation workflows, and end-to-end innovation pipelines, making it a notable infrastructure launch for India’s life science tools segment rather than a routine lab expansion.
- In August 2025, the Department of Biotechnology launched India’s first National Biofoundry Network under the BioE3 policy, bringing together six institutions to scale proof-of-concept biotechnology work into deployable products. The government described the network as a tool-building and biomanufacturing initiative that would strengthen indigenous capabilities, expand biofoundry infrastructure, and help convert laboratory science into usable platforms for research and industry.
Key Market Players
- Becton Dickinson India Private Limited
- Agilent
Technologies India Private Limited
- Illumina
Inc.
- Thermo
Fisher Scientific Inc
- Roche
Products India Private Limited
- Bio-Rad
Laboratories India Private Limited
- Merck
Life Science Private Limited
- Wipro
GE Healthcare Private Limited
- Bruker
India Scientific Pvt Ltd
- Qiagen
India Private Limited
|
By Technology
|
By Product
|
By End Use
|
By Region
|
- Genomic
- Proteomics
- Cell Biology
- Others
|
- Cell Culture Systems & 3D Cell Culture
- Liquid Chromatography
- Mass Spectrometry
- Flow Cytometry
- Cloning & Genomic Engineering
- NGS
- Microscopy
- PCR
- Others
|
- Government
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutions
- Others
|
- East India
- West India
- North India
- South India
|
Report Scope
In this report, the India Life Science Tools Market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- India Life Science Tools
Market, By
Technology:
o Genomic
o Proteomics
o Cell Biology
o Others
- India Life Science Tools
Market, By
Product:
o Cell Culture Systems & 3D Cell Culture
o Liquid Chromatography
o Mass Spectrometry
o Flow Cytometry
o Cloning & Genomic Engineering
o NGS
o Microscopy
o PCR
o Others
- India Life Science Tools
Market, By
End
Use:
o Government
o Pharmaceutical & Biotechnology Companies
o Academic & Research Institutions
o Others
- India Life Science Tools
Market, By Region:
o East India
o West India
o North India
o South India
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the India Life Science Tools Market.
Available Customizations:
India Life Science Tools Market report with the
given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
India Life Science Tools Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]